36 results about "Thoracic aortic aneurysm" patented technology

The present invention provides multilayered materials, such as films usable in particular in medical devices in the form of vascular grafts, biocompatible coverings, and/or inflatable bladders, prosthesis for the endoluminal treatment of aneurysms, particularly aortic aneurysms including both abdominal aortic aneurysms (AAA's) and thoracic aortic aneurysms (TAA's).

Stent-grafts for treating thoracic aortic aneurysms and abdominal aortic aneurysms include graft portions having inflatable channels and graft extensions. The graft extensions include an undulating wire stent and porous, but substantially fluid impermeable, polytetrafluoroethylene (PTFE) graft materials.

The invention provides a coating film capable of adhering or directly adhering on blood vessel. Surface of the inventive artificial blood vessel coating film is coated with a nano-gel coating layer made from mixture of adhesive embolic material and poly(N-isopropylacrylamide). After release of the adhesive embolic material in the nano-gel coating layer, the artificial blood vessel coating film is tightly bonded with blood vessel intima, and simultaneously blocks aneurysm to isolate aneurysm from blood flow. The inventive coating film has the advantages of simple operation during surgery, low cost, and high safety and reliability; is suitable for pathology such as intracranial aneurysms, carotid cavernous fistula (CCF), arteriovenous fistula, thoracic aortic aneurysm and abdominal aortic aneurysm; and has wide application in medical field.

Thoracic aortic aneurysm is a common and lethal disease that requires regular imaging surveillance to determine timing of surgical repair and prevent major complications such as rupture. Current cross-sectional imaging surveillance techniques, largely based on computed tomography angiography (CTA) or magnetic resonance angiography (MRA), are focused on measurement of maximal aortic diameter, although this approach is limited to fixed anatomic positions and is prone to significant measurement error. The present techniques demonstrate novel approaches (generally termed herein “Vascular Deformation Mapping (VDM)”) for assessing changes in aortic dimensions. The present techniques quantify three-dimensional changes in the anatomic dimensions of a vessel through a process that involves non-rigid co-registration of serial imaging data and quantification of vascular deformation on a 3D surface model using some derivation of the spatial deformations resulting from the optimized spatial transform.

The invention discloses a degradable magnesium alloy membranous stent and a membranous stent system and belongs to the field of medical science. The degradable magnesium alloy membranous stent and the membranous stent system comprise a membrane and a degradable magnesium alloy bare stent, wherein the membrane is coated on the outer surface of the degradable magnesium alloy bare stent. The degradable magnesium alloy membranous stent system comprises the degradable magnesium alloy membranous stent, a balloon and a balloon catheter, wherein the degradable magnesium alloy membranous stent is arranged on the outer wall of the balloon, and the balloon is arranged on the balloon catheter. The degradable magnesium alloy membranous stent and the membranous stent system have the advantages of being simple in operation, low in price, low in embolism causing performance and inflammatory response, safe and reliable, and are suitable for pathological changes of intracranial aneurysm, carotid-cavernous sinus fistula, arteriovenous fistula, thoracic aortic aneurysm, abdominal aortic aneurysm and the like.

The invention relates to a high-compliance thoracic aorta covered stent as well as a sizing mould and a sizing method thereof. The high-compliance thoracic aorta covered stent comprises a coating material and a metallic framework, wherein the coating material attaches to the surface of the metallic framework, so that a tubular structure is formed; the coating material is also fixedly connected with the metallic framework by means of medical sutures; the metallic framework comprises a plurality of W-shaped support rings and screw-type support rings, wherein each screw-type support ring is positioned between every two adjacent W-shaped support rings, and the two ends of each screw-type support ring are respectively and fixedly connected with the every two adjacent W-shaped support rings; one end of the coating material is provided with a W-shaped uncoated stent, and the two ends of the coating material are respectively provided with a development mark. The high-compliance thoracic aorta covered stent is used for interventional therapy of thoracic aortic dissection and thoracic aortic aneurysm, and can improve the compliance of a stent main body; after being implanted into the aorta, the stent can better adapt to the form of the aorta, is better in wall adherence, and can reduce complications such as internal leakage and stent-derived new wound which are caused by stent implantation.

The present invention provides methods of treating aneurysmal dilatation, blood vessel wall weakness, and specifically abdominal aortic aneurysm and thoracic aneurysm by inhibiting MMPs and ADAM-10. Such compounds are useful in the in vitro study of the role of MMPs and ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more MMPs or ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm. The invention also comprises methods of treating aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm utilizing the compounds of the invention in conjunction with inhibitors of angiotensin II, including angiotensin II receptor blockers and angiotensin converting enzyme inhibitors, and cyclophilin inhibitors.

The invention relates to the field of biomedicine, in particular to the application of recombinant P-selectin glycoprotein ligand 1 as a target in preparation of drugs for preventing and/or treating aneurysms. PSGL-1 gene knockout mice are taken as a research object. Compared with wild-type mice, the PSGL-1 gene knockout mice has the characteristics that the incidence of thoracic aortic aneurysm and abdominal aortic aneurysm is significantly reduced, collagen deposition is reduced, elastic fiber breakage and smooth muscle cell degradation are significantly inhibited, infiltration of inflammatory cells is significantly reduced, and expression of inflammatory factors, fibrotic factors and adhesion molecules is significantly inhibited. In addition, the adhesion of peripheral blood mononuclearcells to endothelial cells in the absence of PSGL-1 is also significantly reduced. The invention reveals that the loss of PSGL-1 has the effect of inhibiting aneurysms, and a theoretical basis and clinical basis are provided for the role of PSGL-1 in studying new targets and new strategies for preventing and treating aneurysms.

The invention relates to a thoracic descending aorta stent based aneurysm impedance monitoring device and a thoracic descending aorta stent based aneurysm impedance monitoring method. The device comprises a stent graft, an integrated circuit and external processing equipment; the integrated circuit is arranged outside the stent graft and comprises an energy supply module, an impedance measurement sensor, a memory, a data processor and a first radio-frequency transceiving module, and the energy supply module is used for supplying power to the integrated circuit; the impedance measurement sensor transmits detected impedance signals to the data processor through the memory, and then the data processor converts the impedance signals into digital signals, loads ID and timestamp information of the integrated circuit and transmits the digital signals to the external processing equipment through the stent graft by the aid of the first radio-frequency transceiving module to complete functions of data measurement and signal transmission. The thoracic descending aorta stent based aneurysm impedance monitoring device is small in size, low in radiation, capable of monitoring a patient in real time and widely applicable to condition monitoring of descending thoracic aortic aneurysms.

The invention relates to the technical field of biology, in particular to application of a reagent for inhibiting expression of telomerase reverse transcriptase (TERT) in preparation of a medicine for preventing or treating thoracic aortic aneurysm. The invention reveals that the expression level of TERT in aorta media tissues is closely related to the pathogenesis process of thoracic aortic aneurysm for the first time, and verifies that inhibition of TERT can relieve the process of transformation of vascular smooth muscle cells (VSMCs) from a contraction phenotype to a synthetic phenotype, thereby providing a new target and medicine for prevention and treatment of thoracic aortic aneurysm.

The invention belongs to the field of medicine, and relates to application of an intermittent low-oxygen system in a thoracic aortic aneurysm treating device. The invention discloses the new application of the intermittent low-oxygen system which is used for treating the thoracic aortic aneurysm of mammals. It is proved that the intermittent low-oxygen system has an obvious treatment effect on the thoracic aortic aneurysm of the mammals, so that a new approach is provided for the clinic treatment of the thoracic aortic aneurysm. Besides, the invention further provides a device or equipment for treating the thoracic aortic aneurysm, and the device or equipment contains the intermittent low-oxygen system.

The invention discloses a covered stent suitable for thoracic aortic aneurysm and thoracic aortic dissection aneurysm. The covered stent comprises a main path stent and at least one group of movable stents. The main path stent comprises a first cylinder part and a second cylinder part. A vertical partition is arranged in the first cylinder part, and the first cylinder part is divided into a firstflow guide cavity and a second flow guide cavity by the vertical partition. The sectional area of the first flow guide cavity is larger than that of the second flow guide cavity. The second cylinder part and the first cylinder part are integrally formed and communicated with the first flow guide cavity. The movable stent comprises a connecting part and a flow guide part, the connecting part and the flow guide part are integrally formed, and the connecting part is arranged in the second flow guide cavity and tightly attached to the inner wall of the second flow guide cavity. The stent can effectively solve the problem that blood internal leakage is likely to be caused due to the fact that the existing chimney stents are not tightly attached and the chimney stents and aorta are not tightly attached.